Import from '@/components/mdx'

Leqvio (Inclisiran) for ASCVD Secondary Prevention: What Women Need to Know Before Asking Their Doctor

What Is Inclisiran and Why Is "Off-Label" the Right Word Here?

Inclisiran (brand name Leqvio) is a small interfering RNA (siRNA) therapy that silences PCSK9 messenger RNA inside hepatocytes, reducing LDL-cholesterol by roughly 50% from baseline in patients with elevated LDL on maximally tolerated statin therapy. The FDA approved inclisiran in December 2021 for two groups: adults with heterozygous familial hypercholesterolemia (HeFH), and adults with established clinical atherosclerotic cardiovascular disease (ASCVD) who still have LDL ≥70 mg/dL despite maximum-tolerated statin use.

The off-label question is narrower than many women realize. Clinicians sometimes consider inclisiran in patients who have ASCVD but whose LDL is moderately elevated rather than meeting the strict ≥70 mg/dL threshold, or in patients who cannot tolerate any statin at all, placing them outside the "maximally tolerated statin" framing in the label. Some cardiologists also consider it for very-high-risk primary prevention, which sits entirely outside the approved indication.

So when you see headlines about "Leqvio for ASCVD secondary prevention," the question is not whether the drug works for that purpose. It largely does. The question is whether it works well enough, safely enough, and with adequate evidence in women specifically, to justify use beyond the labeled scenario.

How PCSK9 Inhibition Differs From Statins for Women

Statins upregulate LDL receptors on the liver surface. PCSK9 is the protein that degrades those receptors. By silencing PCSK9 production, inclisiran keeps those receptors active longer, pulling more LDL out of circulation. This mechanism is additive to statins, which is why the combination is so effective.

For women, an important sex-specific detail: estrogen naturally suppresses PCSK9 expression, which partly explains why premenopausal women typically have lower LDL than age-matched men. After menopause, PCSK9 suppression by estrogen disappears, LDL rises, and cardiovascular risk accelerates. That biological shift makes PCSK9-targeting therapies theoretically well-suited to postmenopausal women, yet this group has been systematically understudied in inclisiran trials.

The Evidence Gap in Women: A Candid Assessment

The ORION-10 trial, which supported FDA approval for ASCVD patients, enrolled 1,561 participants but only about 28% were women. The ORION-9 trial for HeFH had slightly better female representation at approximately 40%. Neither trial was powered to detect sex-specific differences in hard cardiovascular outcomes. The landmark ORION-4 outcomes trial, which is ongoing with results expected in 2025-2026, will enroll a larger proportion of women, but those data are not yet published.

This means that most of what we know about inclisiran's LDL-lowering magnitude in women is extrapolated from subgroup analyses, not primary outcomes data stratified by sex. The LDL reduction appears consistent between sexes in the data available, but whether that translates to equivalent reductions in myocardial infarction or cardiovascular death in women is genuinely unknown at this time. Honest acknowledgment of that gap matters, because women present with ASCVD differently, often later in life and with atypical symptoms, and their responses to lipid-lowering drugs have not always mirrored men's in outcomes trials.

The Case For Using Inclisiran in ASCVD Secondary Prevention

The rationale for inclisiran in ASCVD secondary prevention is grounded in three overlapping arguments: LDL remains causally linked to cardiovascular events regardless of mechanism used to lower it, adherence to twice-yearly injections may be superior to daily oral pills, and the drug's safety profile is favorable compared to alternatives.

LDL Causality and the "Lower Is Better" Principle

The Cholesterol Treatment Trialists' Collaboration meta-analysis established that each 1 mmol/L (roughly 39 mg/dL) reduction in LDL reduces major vascular events by approximately 22%, independent of the drug class achieving the reduction. ACC/AHA 2022 guidelines classify LDL <70 mg/dL as the target for very-high-risk ASCVD patients, with <55 mg/dL suggested for those with recurrent events. Inclisiran consistently moves patients well into those ranges when added to statin therapy.

Adherence: A Real-World Women's-Health Issue

Medication adherence is not a moral failing. It is a systems problem. Women with ASCVD frequently manage multiple chronic conditions simultaneously, juggle caregiving responsibilities, and face cost barriers that cause pill-taking to slip. A twice-yearly subcutaneous injection given in a clinical setting removes the daily adherence burden entirely. The ORION-3 open-label extension showed sustained LDL reduction of approximately 44% over four years, suggesting the every-six-month dosing is durable in real-world-adjacent conditions.

Side-Effect Profile Compared to Alternatives

Injectional PCSK9 monoclonal antibodies (evolocumab, alirocumab) require every-two-to-four-week self-injection, which some women find burdensome. Statins cause myalgia in approximately 10% of patients in clinical practice, with some evidence that women may be at slightly higher risk of statin-related muscle symptoms. Inclisiran's most common adverse events are injection-site reactions occurring in roughly 8.2% of participants versus 1.8% for placebo. No significant liver toxicity, myopathy, or new-onset diabetes signal has emerged, distinguishing it favorably from long-term high-dose statin use.

The Case Against or the Reasons to Pause

Off-label use carries specific responsibilities that should be weighed carefully for each patient.

No Published Cardiovascular Outcomes Trial for Inclisiran Yet

This is the central clinical gap. Inclisiran is approved based on LDL reduction as a surrogate endpoint, not on demonstrated reductions in heart attacks, strokes, or cardiovascular death in a placebo-controlled outcomes trial. Every other major lipid-lowering therapy now standard in ASCVD prevention, including statins, ezetimibe, evolocumab, and alirocumab, has completed outcomes trials. The FOURIER trial with evolocumab and the ODYSSEY OUTCOMES trial with alirocumab both demonstrated statistically significant reductions in hard cardiovascular events. Inclisiran has not yet published equivalent data, making it a drug with a strong mechanistic and surrogate-endpoint rationale but incomplete outcomes evidence.

For a woman who already meets the FDA-approved indication, this gap is largely acceptable because the LDL-lowering benefit is well-established and the mechanism is validated. For a woman who is being considered off-label, meaning she does not meet the formal HeFH or LDL-threshold criteria, that outcomes gap is a more meaningful reason for caution.

Cost and Insurance Access

Without demonstrated outcomes data, many commercial insurers require prior authorization steps that are lengthy and often denied initially. The list price of inclisiran exceeds $3,500 per injection. Novartis does offer a patient-assistance program, but access is income-dependent and administratively demanding. Women, who statistically earn less than men and are more likely to be uninsured or underinsured, face a disproportionate access burden when off-label use is pursued without a strong insurance pathway.

Guideline Status

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction does not position inclisiran as a first-line or even second-line agent for ASCVD secondary prevention in the general population. It is listed as an option when statins and ezetimibe are insufficient or not tolerated, placing it in the same tier as PCSK9 monoclonal antibodies. Using it more broadly, before trying maximally tolerated statins plus ezetimibe, is not guideline-supported and would represent a departure that requires documented clinical justification.

Sex-Specific Physiology: How Your Hormonal Stage Changes the Calculus

The hormonal stage you are in shapes both your cardiovascular risk and the practical benefit-risk ratio of adding inclisiran.

Reproductive Years (Ages Approximately 18-40)

Women in their reproductive years have lower average LDL and lower ASCVD incidence than age-matched men, largely because of estrogen's LDL-receptor-supporting and PCSK9-suppressing effects. Off-label inclisiran use in this group would be unusual except in confirmed HeFH, where LDL elevations are genetically driven and hormone-independent. If you have HeFH and are in your reproductive years, inclisiran may come up as an option, but contraception requirements (see below) become a central conversation.

Perimenopause (Typically Ages 45-55)

Perimenopause is the phase most often missed in cardiovascular risk conversations. Estrogen fluctuates and then falls, PCSK9 suppression diminishes, and LDL rises at a rate that can add 10-20 mg/dL within two to three years of the final menstrual period. If you have existing ASCVD and you are perimenopausal, your cardiologist may find it harder to keep LDL at target with statins alone. This is a life stage where inclisiran, if you meet the FDA-approved criteria, has a particularly logical application. The off-label question becomes relevant if your LDL is, say, 65 mg/dL, just below the ≥70 threshold, but trending upward as perimenopause progresses.

Postmenopause

Postmenopausal women with ASCVD represent the highest-risk, most undertreated group in cardiovascular medicine. LDL rises, HDL falls, triglycerides increase, and visceral fat accumulates. Women in this group who have confirmed ASCVD and LDL persistently ≥70 mg/dL on maximally tolerated statin are within the FDA-approved label and have the most straightforward risk-benefit argument for inclisiran. Off-label use in this group, for example in women with borderline LDL or with ASCVD risk equivalents rather than confirmed ASCVD, requires individualized discussion about the absence of outcomes data.

Pregnancy, Lactation, and Contraception: Required Reading

Inclisiran is contraindicated in pregnancy. Do not use it if you are pregnant, planning pregnancy in the near term, or breastfeeding.

This is not a theoretical caution. PCSK9 is expressed in fetal liver tissue, and lipids are essential for fetal neural development and membrane synthesis. Animal reproductive studies with inclisiran showed adverse developmental findings at clinically relevant exposures. No adequate human pregnancy data exist, and the drug's mechanism gives no reason to expect it would be safe.

What the FDA Label Actually States

The FDA prescribing information for inclisiran instructs that women of reproductive potential should use effective contraception during treatment and for at least five months after the last dose. This five-month washout period reflects inclisiran's unusually long pharmacodynamic duration, since a single injection suppresses hepatic PCSK9 mRNA for approximately six months.

Lactation

It is not known whether inclisiran is present in human breast milk. Given the lack of data and the long half-life of biological effect, breastfeeding is not recommended during inclisiran treatment or for five months after the final dose. If you are postpartum and breastfeeding and also have a history of ASCVD, discuss timing of treatment resumption with your cardiologist. Maximally tolerated statins compatible with lactation decisions should be discussed with your prescriber, though most statins are also generally discouraged during breastfeeding.

Contraception Requirements

If you are premenopausal and being considered for inclisiran, your prescribing physician should document a contraception plan before initiating the drug. Reliable options include combined oral contraceptives, progestin-only methods, IUDs, or barrier methods used consistently. Given the five-month post-dose washout, if you want to conceive after inclisiran, plan the discontinuation timeline with both your cardiologist and your OB-GYN at least six to eight months before attempting conception.

Who This Is Right For and Who Should Wait

You Are a Stronger Candidate If:

• You have confirmed clinical ASCVD (prior MI, stroke, peripheral artery disease, or coronary revascularization)
• Your LDL remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe
• You are postmenopausal or not planning pregnancy
• You have a history of statin intolerance that limits your ability to reach LDL targets orally
• You prefer clinic-based every-six-month dosing over daily pill burden
• You have confirmed HeFH regardless of LDL level

You Should Pause or Wait If:

• Your LDL is below 70 mg/dL and you do not have confirmed HeFH (off-label territory with weaker rationale)
• You are pregnant, planning pregnancy, or breastfeeding
• You are being considered for primary prevention only (no confirmed ASCVD), which is well outside the label
• You have not yet tried maximally tolerated statin plus ezetimibe (guidelines require this first)
• Cost or insurance access would create significant financial hardship without a clear outcomes-data justification

Female-Relevant Conditions That Interact With This Decision

Several conditions common in women's health affect either cardiovascular risk or lipid metabolism in ways that change how inclisiran fits into your care.

PCOS

Polycystic ovary syndrome is associated with dyslipidemia, insulin resistance, and elevated cardiovascular risk even in younger women. Women with PCOS have a roughly 1.5-fold higher risk of cardiovascular events compared to age-matched women without the condition. If you have PCOS and ASCVD with persistently elevated LDL, you are potentially within the labeled indication and inclisiran may be appropriate. Off-label use in PCOS without confirmed ASCVD or HeFH is not guideline-supported.

Hypothyroidism

Untreated or undertreated hypothyroidism causes secondary hypercholesterolemia. Before attributing an elevated LDL to primary dyslipidemia and escalating to inclisiran, your clinician should confirm your TSH is within a normal range. Thyroid optimization alone can reduce LDL by 20-30 mg/dL in some women, potentially removing the need for an additional agent.

Lupus and Rheumatoid Arthritis

Autoimmune conditions affect women disproportionately and accelerate atherosclerosis through chronic inflammation. Women with lupus or RA who develop ASCVD may find themselves with higher cardiovascular risk than their traditional Framingham risk score captures. If you are in this group and have confirmed ASCVD with elevated LDL on maximal oral therapy, inclisiran is within the approved indication, and the decision is primarily about outcomes evidence and cost.

Practical Questions to Ask at Your Next Appointment

If inclisiran comes up in your clinical visit, whether from your cardiologist, your internist, or a telehealth consultation, these are the questions worth asking out loud:

• Do I meet the FDA-approved criteria, or is this off-label for me specifically?
• Have I truly tried the highest tolerated statin dose plus ezetimibe, and what do my records show?
• What LDL target are we trying to reach and why does inclisiran get me there faster than adding ezetimibe alone?
• Given my age and hormonal status, how does my cardiovascular risk look over the next 10 years?
• What are the realistic out-of-pocket costs, and is there a prior-authorization pathway?
• If I want to have children in the next few years, how does that change the timing decision?

Your clinician should be able to answer each of these clearly. If the conversation leans heavily on LDL numbers without addressing your specific life stage, your hormonal status, and the outcomes-data gap, it may be worth asking for a second opinion from a women's-health cardiologist or a lipid specialist.

Current Guideline Positioning: A Quick Summary

| Guideline | Inclisiran Position | LDL Threshold for Addition | |---|---|---| | ACC/AHA 2022 | Option after statin + ezetimibe failure | ≥70 mg/dL (very high risk) | | ESC/EAS 2021 | Listed alongside PCSK9 antibodies | ≥55 mg/dL (very high risk) or ≥70 mg/dL (high risk) | | NICE (UK) 2023 | Approved for HeFH and ASCVD with LDL above threshold | ≥2.6 mmol/L (≥~100 mg/dL) in certain settings |

No major guideline recommends inclisiran as a first-line secondary prevention agent or endorses its use when LDL is already below target on oral therapy.